CABA News and Press, Cabaletta Bio Inc.

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Comp...

PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Comp...

2026-01-27 11:01:47 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Cabaletta Bio: Do You Buy With The Insiders?

2026-01-22 08:08:24 ET More on Cabaletta Bio Cabaletta Bio, Inc. (CABA) Presents At Citi Annual Global Healthcare Conference 2025 Transcript Seeking Alpha’s Quant Rating on Cabaletta Bio Historical earnings data for Cabaletta Bio Financial information ...

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose  IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform b...

2025-12-03 17:23:35 ET Cabaletta Bio, Inc. (CABA) Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:45 PM EST... Read the full article on Seeking Alpha For further details see: Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 202...

2025-11-26 15:13:03 ET More on Markets The 'Real' Economy Is In Real Trouble Boomer Blues, Not Gen Z? SPYI Vs. SPY: The Case For Covered Calls In Two Charts Mixed signals as S&P 500’s December strength weakens in recent decade Sociét&#...

2025-11-14 02:24:24 ET Editor's note: Seeking Alpha is proud to welcome Holger Kujath as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium...

2025-11-10 07:40:22 ET More on Cabaletta Bio Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon Seeking Alpha’s Quant Rating on Cabaletta Bio Historical earnings data for Cabaletta Bio Financial information for Cabaletta Bio ...

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who ...